Mostly affects ages 50 to 70.(1)
Approximately 40,000 new cases are diagnosed each year in Europe alone.(2)
Prognosis is poor, with a median survival of ∼3 years.(3)
No cure exists: current treatments focus on slowing the progression of the disease and improving quality of life.(4)
AstraZeneca has so far added five novel targets to its drug portfolio — three for IPF and two for CKD. The collaboration was also expanded for a further three years into two new disease areas — heart failure and systemic lupus erythematosus — in January 2022.
(1) Mediline Plus. Idiopathic pulmonary fibrosis. Available from: https://medlineplus.gov/genetics/condition/idiopathic-pulmonary-fibrosis/ [Accessed April 2021]
(2) Sauleda J, Núñez B, Sala E, Soriano JB. Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Med Sci (Basel). 2018;6(4):110. Published 2018 Nov 29. doi:10.3390/medsci6040110.
(3) Navaratnam, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UKThorax 2011;66:462-467.
(4) National Heart, Lung and Blood Institute. Idiopathic Pulmonary Fibrosis. Available from: https://www.nhlbi.nih.gov/health-topics/idiopathic-pulmonary-fibrosis [Accessed April 2021].